Vanrafia also interacts with medicines that are called strong or moderate inducers of CYP3A. When Vanrafia is taken with these CYP3A inducers, it may not work as well to treat your IgAN.

Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program 1 Phase III data showed ...

Vanrafia's accelerated approval is the third in the US for the company’s kidney disease portfolio, following the agency’s approvals for Fabhalta in C3 glomerulopathy in March 2025 and another ...

Vanrafia is supplied as a 0.75mg tablet. The prescribing information for Vanrafia includes a Boxed Warning for embryo-fetal toxicity; the product is contraindicated for use in pregnant patients.

There's a long history behind atrasentan, the drug that became Vanrafia. It's an endothelin A receptor antagonist. These drugs bind to, and block, the action of endothelin to widen the blood vessels.

Vanrafia is Novartis’ second IgAN drug to reach the market. Before that, the company’s complement inhibitor Fabhalta expanded into IgAN in August 2024.

The FDA has approved Vanrafia (atrasentan), a once-daily pill that reduces proteinuria in adults with immunoglobulin A nephropathy (IgAN), offering new hope for slowing kidney damage.

Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, for ...

Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation ...

Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1 Phase III data showed ...